CVS Health CVS

CVS Health has seen significant stock appreciation, with shares rising over 9% after a strong first-quarter earnings report that exceeded analyst expectations. The company reported revenues of $100.4 billion and adjusted earnings per share of $2.57, leading to an increased full-year adjusted EPS forecast of $7.30 to $7.50. This follows a robust Q3 performance in 2022, where CVS generated $81.2 billion in revenues and raised its adjusted EPS guidance, buoyed by hedge fund optimism. Investors are increasingly confident in CVS's growth potential, as its stock price has appreciated by approximately 30% over the past year.